Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 12/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 12/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 10/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808033 | 0.95 | ITGB1 (0.35) | ITGB1ITGA4ITGB7ITGAVALDH1A1 | |
| SCHEMBL5164317 | 0.93 | ITGB1 (0.38) | ITGB1ITGA4ITGB7ITGAVKMT2A | |
| Hydrochloric Acid SCHEMBL2769223 | 0.92 | ITGB1 (0.38) | ITGB1ITGA4ITGB7ITGAVKMT2A | |
| SCHEMBL2809357 | 0.92 | ITGB1 (0.35) | ITGB1ITGA4ITGB7ITGAVKMT2A | |
| SCHEMBL2770210 | 0.90 | ITGB1 (0.36) | ITGB1ITGA4ITGB7ITGAVALDH1A1 | |
| SCHEMBL2771648 | 0.90 | ITGB1 (0.36) | ITGB1ITGA4ITGB7ITGAVBRAF | |
| SCHEMBL2814333 | 0.89 | ITGB1 (0.35) | ITGB1ITGA4ITGB7KMT2AMAPT | |
| SCHEMBL2770505 | 0.89 | ITGB1 (0.36) | ITGB1ITGA4ITGB7ITGAVBRAF | |
| SCHEMBL2773314 | 0.89 | ITGB1 (0.35) | ITGB1ITGA4ITGB7 | |
| SCHEMBL4210082 | 0.87 | ITGB1 (0.37) | ITGB1ITGA4ITGB7ITGAVALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231185-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | Elan Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-1507533-B1 | HETEROARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA-4 INTEGRINS | ELAN PHARM INC (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| WO-2009075806-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| EP-1635871-A4 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1635871-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-7008949-B2 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2006-03-07 | — | — | US | disclosed |
| US-20060004019-A1 | Steroid sparing agents and methods of using same | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2006-01-05 | — | — | US | disclosed |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2005000244-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040142954-A1 | Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha4 integrins | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004019-A1 | Steroid sparing agents and methods of using same | IL5, FCER2, CD40 | ITGB1 305/4885ITGA4 298/4885ITGB7 485/4885 |
| US-20040142954-A1 | Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha4 integrins | VCAM1, ITGB4, ITGA4 | ITGB1 10/4885ITGA4 3/4885ITGB7 30/4885 |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | ITGB1 8/4885ITGA4 3/4885ITGB7 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.